Oppenheimer Reiterates Outperform on Relay Therapeutics, Maintains $33 Price Target
Portfolio Pulse from richadhand@benzinga.com
Oppenheimer analyst Matthew Biegler has reiterated his 'Outperform' rating on Relay Therapeutics (NASDAQ:RLAY), maintaining a price target of $33.
August 09, 2023 | 2:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer analyst Matthew Biegler has reiterated his 'Outperform' rating on Relay Therapeutics, maintaining a price target of $33.
The reiteration of the 'Outperform' rating and the maintenance of the $33 price target by Oppenheimer analyst Matthew Biegler indicates a positive outlook for Relay Therapeutics. This could potentially lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100